Cenderitide

Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC) . Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP) . Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research[1][2][3].

Product Specifications

CAS Number

[507289-11-4]

UNSPSC

12352209

Target

Guanylate Cyclase

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/cenderitide.html

Purity

99.84

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

[Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Pro-Ser-Leu-Arg-Asp-Pro-Arg-Pro-Asn-Ala-Pro-Ser-Thr-Ser-Ala(Disulfidebridge:Cys6-Cys22)]

Molecular Formula

C158H263N49O50S3

Molecular Weight

3745.27

References & Citations

[1]Ichiki T, et al. Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol. 2019 Apr 15;281:166-171. |[2]Wojta J. Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2 (2) :106-7. |[3]Lisa C Costello-Boerrigter, et al. Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure. BMC Pharmacol 11 (Suppl 1), P18 (2011) .|[4]Lisy O, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008 Jul 1;52 (1) :60-8.